Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalazatide in active plaque psoriasis
NCT02435342Phase 1Completed
- Sponsor
- Kineta Inc.
- Start
- Oct 2014
- Primary completion
- Mar 2015
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dalazatide in plaque psoriasis (2 arms), sponsored by Kineta Inc. Primary endpoint: Subjects with adverse events at Day 57. Started Oct 2014; status: completed.
02
Drugs
dalazatide
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02435342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435342.